Work

Supplementary Materials from Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer

Year: 2023

Type: supplementary-materials

Abstract: Table S1. Antibodies used for flow cytometry Table S2. Monte Carlo cross-validation of continuous measure markers. Table S3. Monte Carlo cross-validation of dichotomous measure markers. Table S4. Pancreatic cancer patient circulating immune cell frequencies Figure S1. Overall survival does not predict plasma MCP-1 levels

DOI: 10.1158/1078-0432.22458237

Authors: Matthew R. Farren, Thomas A. Mace, Susan Geyer, Sameh Mikhail, Christina Wu, Kristen Ciombor, Sanaa Tahiri, Daniel Ahn, Anne M. Noonan, Miguel Villalona-Calero, Tanios Bekaii-Saab, Gregory B. Lesinski

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362397053

Cites:

Cited by:

Related to: 10